Vaxart's Oral COVID-19 Pill Shows Safety in Phase 2b Trial; Cash Runway Extends into 2027
Event summary
- Vaxart reported topline safety data from a 400-person sentinel cohort in its Phase 2b COVID-19 trial, showing no vaccine-related serious adverse events.
- The company has $64.0 million in cash as of June 30, 2026, with a runway into the second quarter of 2027.
- Vaxart secured an additional $344.8 million in funding from BARDA for its Phase 2b COVID-19 study.
- Revenue for Q2 2026 was $27.2 million, down from $39.7 million in Q2 2025.
The big picture
Vaxart's positive safety data for its oral COVID-19 pill positions it as a potential disruptor in the vaccine delivery space, competing with traditional mRNA vaccines. The company's ability to secure additional BARDA funding and extend its cash runway reflects confidence in its platform, but success will hinge on demonstrating efficacy in larger trials and navigating a market where COVID-19 vaccine demand may be waning.
What we're watching
- Clinical Efficacy
- Whether the oral pill vaccine demonstrates comparable efficacy to mRNA vaccines in the main cohort study results expected in early 2027.
- Funding Strategy
- How Vaxart will extend its cash runway beyond Q2 2027 through partnerships and non-dilutive funding options.
- Market Positioning
- The pace at which Vaxart can commercialize its oral vaccine platform against competitors in the evolving COVID-19 vaccine market.
Related topics